Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Juan Ramos Acevedo

Neurological Surgery Caguas, PR Medical Doctor

NPI 1528256518 CMS profile 577307

Ave Luis Munoz Marin 100 Esq Degetau Ste 706, Dr Juan M Ramos Neuro Endo, Caguas, PR 00726

Open in the dashboard

General payments

$3,331

61 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Juan Ramos Acevedo of Caguas, PR is reported in the CMS Open Payments database as having received $3,331 across 61 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 51st percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $780 16
2024 General $942 20
2023 General $590 10
2022 General $237 3
2021 General $167 2
2020 General $194 3
2019 General $422 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Juan Ramos Acevedo
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Juan Ramos Acevedo were reported at $780. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Juan Ramos Acevedo Neurological Surgery median Middle half National median
2019 $422 $582 $138–$3,006 $163
2020 $194 $294 $76–$2,174 $114
2021 $167 $387 $105–$2,432 $132
2022 $237 $542 $139–$2,989 $149
2023 $590 $534 $145–$2,697 $160
2024 $942 $574 $155–$3,046 $164
2025 $780 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $1,888 37 payments
  2. Penumbra, Inc. $923 15 payments
  3. Carl Zeiss Meditec USA, Inc. $157 1 payment
  4. Janssen Pharmaceuticals, Inc $118 2 payments
  5. Zimmer Biomet Holdings, Inc. $94 1 payment
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $79 1 payment
  7. Abbott Laboratories $23 1 payment
  8. Johnson and Johnson International $20 1 payment
  9. Cordis US Corp. $17 1 payment
  10. Terumo Medical Corporation $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,311 60 payments
  2. Travel and Lodging $20 1 payment
Products named General payments · program years 2019–2025
  1. Pipeline $617 10 payments
  2. SOLITAIRE X $497 10 payments
  3. AXIUM PRIMETM $256 6 payments
  4. Penumbra System Neurointervention $206 2 payments
  5. RED 72 $192 5 payments
  6. Smart Coil $192 3 payments
  7. Smart $166 2 payments
  8. IORT $157 1 payment
  9. Penumbra System Neurointervention $134 2 payments
  10. Micra $127 1 payment
  11. Other $838 22 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

146

Median for Neurosurgery: 83

Drug cost

$9,127

Median for Neurosurgery: $872

Branded share of claims

61%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Brilinta Ticagrelor Brand 12 $5,484
Oxcarbazepine Generic 31 $1,674
Carbamazepine Er Carbamazepine Brand 12 $1,195
Clopidogrel Clopidogrel Bisulfate Brand 65 $626
Lamotrigine Generic 11 $83
Famotidine Generic 15 $66

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$17,276

Medicare's payments for the services billed

Medicare patients

22

Average age 75

Services billed

70

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 64%
Arthritis 55%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

61 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in Puerto Rico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record